Company Overview of Lupin Pharmaceuticals, Inc.
Lupin Pharmaceuticals, Inc. engages in the development and manufacture of branded and generic pharmaceutical products. It offers generic pharmaceutical products for a range of therapeutic areas; and generic Gatifloxacin Ophthalmic Solution for the treatment of bacterial conjunctivitis. The company also engages in identifying, developing, and marketing prescription drugs for children through distributors in the United States; and manufactures oral and injectable cephalosporin APIs. In addition, it offers oral contraceptives for the prevention of pregnancy in women. Lupin Pharmaceuticals, Inc. was founded in 2003 and is based in Baltimore, Maryland. The company has plants in Mandideep, Auranga...
111 South Calvert Street
Baltimore, MD 21202
Founded in 2003
Key Executives for Lupin Pharmaceuticals, Inc.
Chief Executive Officer and Managing Director
Compensation as of Fiscal Year 2015.
Lupin Pharmaceuticals, Inc. Key Developments
Horizon Pharma plc Files Patent Infringement Lawsuits Against Actavis Laboratories UT, Inc., Actavis, Inc., Allergan plc, Amneal Pharmaceuticals, LLC, IGI Laboratories, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd
Jul 6 15
Horizon Pharma plc announced it has filed patent infringement lawsuits in the United States District Court for the District of New Jersey against Actavis Laboratories UT, Inc., Actavis, Inc., and Allergan plc (collectively Actavis), Amneal Pharmaceuticals, LLC (Amneal), IGI Laboratories, Inc. (IGI), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), and Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries Ltd. (collectively Taro) related to Abbreviated New Drug Applications filed with the U.S. Food and Drug Administration to market a generic version of PENNSAID(r) (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). The lawsuits claim infringement of Horizon's newly issued U.S. Patent No. 9,066,913 titled 'Diclofenac Topical Formulation', which covers PENNSAID 2%.
Lilly and Acrux File Patent Infringement Lawsuit Against Lupin Pharma
Jul 6 15
Acrux announced that Eli Lilly and Co., Eli Lilly Export S.A., and Acrux DDS Pty Ltd. have filed a lawsuit against Lupin Pharmaceuticals Inc. for infringement of issued US patents that cover Axiron. The patents are owned by Acrux DDS Pty Ltd, a wholly-owned subsidiary of Acrux Limited, and are exclusively licensed to Lilly. The lawsuit was filed in the United States District Court for the Southern District of Indiana in response to a notice letter sent by Lupin regarding its filing with the FDA of an Abbreviated New Drug Application (ANDA) for a Testosterone Metered Dose Transdermal Solution. The letter stated that the ANDA contains Paragraph IV certifications with respect to US Patents 8,419,307, 8,435,944, 8,784,878, 8,807,861 and 8,993,520, which are expected to expire between 2026 and 2030. These patents include claims relating to the application of testosterone formulations to the underarm and to the applicator used to apply Axiron.
Lupin Pharmaceuticals Inc. Launches Amlodipine and Valsartan Tablets in US
Apr 1 15
Lupin Pharmaceuticals Inc. has launched its Amlodipine and Valsartan Tablets, 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320 mg, which are the AB rated generic equivalent of Novartis Pharmaceuticals Corporation's Exforge tablets 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320mg strengths. Lupin had received final approval from the United States Food and Drug Administration (FDA) for the product. Lupin's Amlodipine and Valsartan Tablets is the combination tablet of Amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and Valsartan, an angiotensin II receptor blocker (ARB). Lupin's Amlodipine and Valsartan tablets are indicated for the treatment of hypertension and to lower blood pressure: In patients not adequately controlled on monotherapy; As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Exforge Tablets had U.S sales of USD 414.9 million.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|